Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
T-Rex 2X Inverse MSTR Daily Target ETF
MSTZ
5
Direxion Daily S&P 500 Bear 3X Shares ETF
SPXS
US Stock MarketDetailed Quotes
RGLS Regulus Therapeutics
- 3.231
- +0.471+17.05%
Trading Apr 28 10:37 ET
214.01MMarket Cap-3.94P/E (TTM)
3.280High2.758Low1.11MVolume2.780Open2.760Pre Close3.43MTurnover2.47%Turnover RatioLossP/E (Static)66.24MShares3.26052wk High2.80P/B144.97MFloat Cap0.83052wk Low--Dividend TTM44.87MShs Float3071.997Historical High--Div YieldTTM18.93%Amplitude0.760Historical Low3.093Avg Price1Lot Size
About Regulus Therapeutics Company
Regulus Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of drugs targeting microRNAs. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease. RGLS4326 is an anti-miR targeting miR-17 in Phase I clinical trial for the treatment of autosomal dominant polycystic kidney disease. The firm is also developing a pipeline of preclinical drug product candidates in renal, hepatic, and central nervous systems diseases. The company was founded in 2007 and is headquartered in San Diego, CA.
Company Profile
SymbolRGLS
Company NameRegulus Therapeutics
Listing DateOct 4, 2012
Issue Price4.00
Founded2007
CEOMr. Joseph P. Hagan
MarketNASDAQ
Employees30
Fiscal Year Ends12-31
Address4224 Campus Point Court,Suite 210
CitySan Diego
ProvinceCalifornia
CountryUnited States of America
Zip Code92121
Phone1-858-202-6300
Websitehttp://www.regulusrx.com
Company Executives
- Name
- Position
- Salary
- Joseph P. Hagan
- Director and Chief Executive Officer
- 2.57M
- Crispina Calsada
- Chief Financial Officer
- 1.07M
- Daniel Penksa
- Vice President, Finance, Controller and Principal Accounting Officer
- --
- Christopher Aker
- Senior Vice President and General Counsel
- 1.09M
- Dr. Stelios Papadopoulos,PhD
- Chairman of the Board
- 131.44K
- Dr. Preston Klassen,M.D.
- Director, President and Head of Research and Development
- --
- Pascale Witz, M. Sc.,M.B.A.
- Independent Director
- 93.44K
- Kathryn J. Collier
- Independent Director
- 107.44K
- Jake R. Nunn
- Independent Director
- 97.44K
- Dr. William H. Rastetter,PhD
- Independent Director
- 99.44K
- Dr. Hugh Rosen, M.D.,PhD
- Independent Director
- 93.44K
- Dr. David Baltimore, PhD
- Independent Director
- 95.44K
- Dr. Alice Shih-hou Huang, PhD
- Independent Director
- 93.44K
Market Insights
Discussing
2025 Buffett shareholders' meeting: What's the new buzz in value investing?
🎙️Discussion 1. In the face of market changes, do you prefer to stick with growth stocks or switch to value stocks? 2. Based on the current
Moomoo News Global
Apr 9 20:29
Learning From Buffett: Investing Wisely Amid Market Volatility Triggered by Trump's Tariffs
Discussing
FOMC holds rates amid heightened uncertainty: Where will US stocks head next?
🎙️Discussion 1. With the Fed highlighting "elevated uncertainty", are you prioritizing rate projections or near-term economic data for ma
Moo Live
Mar 20 02:25
FOMC Press Conference, March 19, 2025
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
Unlock Now